TY - JOUR
T1 - Building a network of TP53 and IGHV testing reference centers across Spain
T2 - the Red53 initiative
AU - Bosch, Francesc
AU - Navarro, Blanca
AU - Crespo, Marta
AU - Alcoceba, Miguel
AU - Sánchez, Julio Bravo
AU - Tazón, Barbara
AU - Serrano, Alicia
AU - Álvarez, María García
AU - Serrano, Lydia González
AU - Alonso-Torres, Pablo
AU - Villanueva, Miguel
AU - Loriente, Cristina
AU - Abrisqueta, Pau
AU - Peiró, Manel
AU - García-Marco, José Antonio
AU - González, Marcos
AU - Terol, María José
N1 - Funding Information:
FB has received research funding and honoraria from Roche, Celgene, Takeda, AstraZeneca, Novartis, Abbie, and Janssen. MC has received research funding from Karyopharm, Pharmacyclics, Roche, Arqule, and AstraZeneca. PA has received honoraria from Janssen, Roche, Celgene, and Abbie. MG has received research funding from Gilead Sciences and honoraria from AbbVie, Gilead, Janssen, and Roche. MA has received honoraria and/or non-financial support from AbbVie, Janssen, and Roche. MT has received research funding and honoraria from Roche, Celgene, Takeda, AstraZeneca, AbbVie, and Janssen. JAGM has received research funding and honoraria from AbbVie, Gilead, Janssen, and Roche. JBS has received research funding from AbbVie, and LGS has received research funding from Janssen. BN and AS have received honoraria from Janssen.
Funding Information:
This work was supported in part by Janssen Pharmaceutical Companies of Johnson & Johnson. MC holds a contract from Ministerio de Ciencia, Innovación y Universidades (RYC-2012-12018).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/3
Y1 - 2021/3
N2 - Among the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing with CLL patients. To provide this molecular testing across the country, the Spanish Cooperative Group on CLL (GELLC) established a network of four analytical reference centers. A total of 2153 samples from 256 centers were analyzed over a period of 30 months. In 9% of the patients, we found pathological mutations in the TP53 gene, whereas 48.96% were classified as IGHV unmutated. Results of the satisfaction survey of the program showed a Net Promoter Score of 85.15. Building a national network for molecular testing in CLL allowed the CLL population a broad access to complex biomarkers analysis that should translate into a more accurate and informed therapeutic decision-making.
AB - Among the different biomarkers predicting response in chronic lymphocytic leukemia (CLL), the most influential parameters are the mutational status of the IGHV genes and the presence of TP53 gene disruptions. Nevertheless, these important assessments are not readily available in most centers dealing with CLL patients. To provide this molecular testing across the country, the Spanish Cooperative Group on CLL (GELLC) established a network of four analytical reference centers. A total of 2153 samples from 256 centers were analyzed over a period of 30 months. In 9% of the patients, we found pathological mutations in the TP53 gene, whereas 48.96% were classified as IGHV unmutated. Results of the satisfaction survey of the program showed a Net Promoter Score of 85.15. Building a national network for molecular testing in CLL allowed the CLL population a broad access to complex biomarkers analysis that should translate into a more accurate and informed therapeutic decision-making.
KW - CLL
KW - IGHV mutational status
KW - Laboratory network
KW - TP53 gene mutations
UR - http://www.scopus.com/inward/record.url?scp=85099037059&partnerID=8YFLogxK
U2 - 10.1007/s00277-020-04331-9
DO - 10.1007/s00277-020-04331-9
M3 - Article
C2 - 33409623
AN - SCOPUS:85099037059
SN - 0939-5555
VL - 100
SP - 825
EP - 830
JO - Annals of Hematology
JF - Annals of Hematology
IS - 3
ER -